← Back to Clinical Trials
Recruiting NCT05550077

NCT05550077 Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05550077
Status Recruiting
Phase
Sponsor jiaoliqun
Condition Intracranial Atherosclerosis
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2020-03-15
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Optical Coherence TomographyPercutaneous transluminal angioplasty and stenting

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2020-03-15 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).

Eligibility Criteria

Inclusion Criteria: * Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours * Stenotic degree ≥ 50%, measured by digital subtraction angiography * The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery) Exclusion Criteria: * Arteriovenous Malformation * Aneurysm

Contact & Investigator

Central Contact

Liqun Jiao, Professor

✉ liqunjiao@sina.cn

📞 +8613911224991

Frequently Asked Questions

Who can join the NCT05550077 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Intracranial Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05550077 currently recruiting?

Yes, NCT05550077 is actively recruiting participants. Contact the research team at liqunjiao@sina.cn for enrollment information.

Where is the NCT05550077 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT05550077 clinical trial?

NCT05550077 is sponsored by jiaoliqun. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology